title: [Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
abstract: OBJECTIVE
  To compare the efficacy and toxicity of neoadjuvant chemotherapy of docetaxel with paclitaxel plus pirarubicin hydrochloride (THP) and cyclophosphamide (CTX) in locally advanced breast cancer (LABC).
  
  
  METHODS
  A total of 97 LABC cases were randomly divided into 2 groups: docetaxel group (n = 49, taxotere plus THP & CTX) and paclitaxel group (n = 48, paclitaxel plus THP & CTX). Neoadjuvant chemotherapy had four cycles of 21 days each.
  
  
  RESULTS
  The clinical and pathological complete remission rates of docetaxel group was 28.6% and 26.5% respectively. They were significantly higher than those of paclitaxel group (10.4% and 8.3%). Furthermore the pathological negative rate of regional lymph node in docetaxel group was also significantly higher than that of paclitaxel group (40.6% vs. 12.9%). However, grade III-IV blood system toxic reaction was found in 71.4% cases, grade II-IV liver dysfunction in 53.1% cases and edema in 24.5% cases among docetaxel group. They were higher than those among paclitaxel group (46.9%, 27.1% & 4.2%).
  
  
  CONCLUSIONS
  Compared with paclitaxel, the combined regimen of docetaxel plus THP and CTX offers better outcomes for locally advanced breast cancer.
authors.affiliation: Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Su
authors.forename: Meng-quan
authors.initials: MQ
authors.lastname: Li
authors.forename: Han
authors.initials: H
authors.lastname: Xu
authors.forename: Di
authors.initials: D
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D017239:Paclitaxel